A new reality for Immunocore
A private raise should crystallise what was already known to have been a valuation comedown for Immunocore and its troubled investor Neil Woodford.
Upcoming events – Aurinia and Principia face autoimmune tests
Aurinia hopes to light up with Aurora data, while Principia's BTK inhibitor PRN1008 is put to the test.
Sakura blossoms for Roche, setting up Soliris battle
A phase III win for Roche’s satralizumab has added to Alexion’s Soliris woes.
Go or no go? Novo awaits call on oral sema
The Danish group tops the list, while Ardelyx could get its first nod for tenapanor, and Xeris gets a second shot with its hypoglycaemia rescue pen.
Second time lucky for Astra in lupus
The extensively overhauled Tulip-2 study of anifrolumab in lupus is an unexpected success.
Six burning Otezla questions
Planned divestment of Celgene’s psoriasis blockbuster means instant cashback for Bristol, a result the markets see as a win-win-win.
Upcoming events – Rare disease data due from Chemocentryx and Sanofi
Chemocentryx and Sanofi are looking to target the complement pathway in ANCA-associated vasculitis and cold agglutinin disease respectively, with phase III data due in…
Novartis cast-off gives Pharming a gap-filler
Pharming picks up Novartis’s late-stage PI3K inhibitor and plans to launch it for an ultra-rare disease. How will the competition respond?
Strike two for overheated South Korean biotech
Pexa-Vec fails earlier than expected, dealing exuberant South Korean biotech investors and the oncolytic virus field another blow.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.